Get to know our clinical trials
Multicenter, open-label, dose-escalation Phase I study to evaluate the safety and pharmacokinetics of ro7425781 in participants with relapsed or refractory multiple myeloma.
THE MAIN OBJECTIVES OF THIS STUDY ARE AS FOLLOWS: TO EVALUATE THE SAFETY OF DIFFERENT DOSES OF RO7425781 TO CHECK WHAT SIDE EFFECTS RO7425781 HAS ON THE PATIENT. TO COLLECT DATA TO FIND OUT IF RO7425781 IS EFFECTIVE AGAINST MULTIPLE MYELOMA WHEN GIVEN ALONE. FIND OUT HOW RO7425781 IS DISTRIBUTED AND ELIMINATED FROM THE BODY.
Technical Summary
- MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF RO7425781 IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
- Code EudraCT: 2020-002012-46
- Protocol number: BP42233
- Promoter: F. Hoffmann-La Roche Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.